Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injec
-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...
Source: pharmiweb.com
